



# MASTER TRIAL LIST

AUGUST 2022

**\*\*\*NEW & REOPENED TRIALS HIGHLIGHTED IN GREEN!\*\*\***

**JUST IN TIME TRIALS (JIT)**

AML	ANAL	ALL
APL	BLADDER-UROTHELIAL	BRAIN
BREAST/ GYN	CANCER CONTROL	
CLL	CML	COLON-RECTAL
ESOPHAGEAL - GASTRIC	HEAD & NECK	LYMPHOMA
MDS	MELANOMA	MERKEL
MOLECULAR STUDIES	MULTIPLE MYELOMA	NEUROENDOCRINE
NSCLC	PANCREATIC	PROSTATE
RADIATION TRIALS	RENAL CELL	SMALL CELL LUNG CANCER

Updated 7.29.22

**RADIATION LOCATIONS:**

- OSF Glen Oak - OSF main hospital
- OSF Route 91 (attached to Illinois CancerCare)
- UPHM - Unity Point Health Methodist
- Galesburg - Western Illinois Cancer Treatment Center
- SJMC - St Joseph Medical Center



**JUST IN TIME (JIT) TRIALS**

\*Contact Disease Specific Navigator

**Multi-Disease Site: Advanced/Metastatic Solid Tumors**

[RAIN-3202](#)

A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors

**Carcinoid**

[S2104](#)

Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors

**Gastrointestinal**

[EA2187](#)

*Temporarily closed* Phase II study of Pevonedistat in Combincatoin with Carbo and paclitaxel in advanced intrahepatic cholangiocarcinoma.

**Genitourinary - Rare**

[A031702](#)

Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors (*temp closed cohorts - small cell carcinoma/neuroendorine & adenocarcinoma of bladder, penile, and misc GU tract variants, renal medullary carcinoma, and rare GU*)

**Head & Neck**

[EA3191](#)

**Temporarily Closed (RT at Route-91)** A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features

**Lung**

[S1934](#)

Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer. **NASSIST** (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors)

**Multi-Disease**

[S1614](#)

*(temp closed)* A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or past hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors

**Pancreas**

<b><u>S2001</u></b>	Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations
<b><u>S2104</u></b>	Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
<b>Rectal</b>	
<b><u>EA2201</u></b>	<b>(RT at Glen Oak, UPHM, Galesburg)</b> A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma
<b>Sarcoma</b>	
<b><u>A091902</u></b>	A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma <i>(closed to taxane pre-treated pts only)</i>
<b>Skin</b>	
<b><u>A091802</u></b>	Phase II randomized Trial of Avelumab plus cetuximab versus avelumab alone in advanced cutaneous Squamous cell carcinoma of skin
<b>Thymoma</b>	
<b><u>S1701</u></b>	A Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma

# MASTER TRIAL LIST

AUGUST 2022

[MENU](#)

**AML**

Navigator - Heather x3661



# MASTER TRIAL LIST

AUGUST 2022



## ANAL

Navigator - Carrie x3621

<a href="#"><u>EA2176</u></a>	A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients
<a href="#"><u>EA2182</u></a>	<b>(RT at UPHM and Glen Oak)</b> A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)



ILLINOIS  
CANCERCARE, P.C.

*Specializing in Cancer and Blood Disorders*

# MASTER TRIAL LIST

AUGUST 2022

[MENU](#)

*APL*

Navigator - Heather x3661

*There are no trials available at this time*



# MASTER TRIAL LIST

AUGUST 2022

MENU

## ACUTE LYMPHOBLASTIC LEUKEMIA

Navigator - Heather x3661

[EA9152](#)

**Temporarily Closed** | A Phase IB/II Study of Venetoclax (ABT-199) in Combination With Liposomal Vincristine in Patients With Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia



# MASTER TRIAL LIST

AUGUST 2022



## BLADDER / UROTHELIAL

Navigator - Carrie x3621

### ADJUVANT / NEOADJUVANT

<p><a href="#"><u>BMS CA017-078</u></a></p>	<p><b>(Peoria, Bloomington, Galesburg, and Peru)</b> -A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer (<i>BMS-986205/placebo tablets discontinued</i>)</p>
<p><a href="#"><u>EA8185</u></a></p>	<p><b>(RT pending at Glen Oak &amp; Rt-91)</b> Phase 2 Study of Bladder-Sparing Chemoradiation With MEDI4736 (Durvalumab) in Clinical Stage 3, Node Positive Bladder Cancer (INSPIRE)</p>
<p><a href="#"><u>S1806</u></a></p>	<p><b>(RT at Glen Oak, SJMC, UPHM and Galesburg)</b> Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer</p>
<p><a href="#"><u>S2011</u></a></p>	<p>Randomized Phase II Trial of Gemcitabine, Avelumab and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma: SWOG GAP TRIAL</p>
<h3>METASTATIC</h3>	
<p><a href="#"><u>A031901</u></a></p>	<p>Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial</p>
<p><a href="#"><u>A032001</u></a></p>	<p>Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients With Metastatic Urothelial Cancer</p>



A032002

**(RT at Glen Oak)** Phase II Randomized Trial of Atezolizumab Versus Atezolizumab and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (ART)



# MASTER TRIAL LIST

AUGUST 2022



## BRAIN

Navigator - Carrie x3621

<a href="#"><u>A071702</u></a>	A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
<a href="#"><u>BN007</u></a>	<b>Temporarily Closed (RT at UPHM, Glen Oak, Galesburg)</b> A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
<a href="#"><u>BN011</u></a>	<b>(RT credentialing pending)</b> A Phase III Trial of Gleostine® (Lomustine)-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients With Methylated MGMT Promoter Glioblastoma
<a href="#"><u>N0577</u></a>	<b>(RT at Glen Oak, RT 91, and UPHM)</b> Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma



**BREAST**

Navigator - Angie x3613

**DCIS**

[AFT-25](#)

Comparing an Operation to Monitoring, With or Without Endocrine Therapy Trial For Low Risk DCIS: A Phase III Prospective Randomized Trial (**COMET**)

**NEO/ADJUVANT TREATMENT**

**Neo/Adjuvant - HER2 Positive**

[EA1181](#)

Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response (CompassHER2-pCR) (*Closed to Her2+/ER+ w/ tumor 2.1-3cm and node negative*)

**Neo/Adjuvant - Hormone Receptor Positive / HER2 Negative**

[BR007](#)

(RT at Galesburg, Glen Oak, Rt 91, UPHM, SJMC) Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer

**Neo/Adjuvant - Triple Negative**

**METASTATIC TREATMENT**

**Metastatic - HER2 Positive**

**Metastatic - Hormone Receptor Positive / HER2 Negative**

**Metastatic - Triple Negative**

**SURGERY / RADIATION ONLY**

[MA.39](#)

Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer (*RT: Glen Oak and UPHM*)

**CANCER CONTROL (Breast only)**

[A191901](#)

(Peoria, Bloomington, Galesburg, Ottawa, Pekin, and Peru) Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions (*only enrolling African American women*)

[A211901](#)

Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions

<a href="#"><u>A222004</u></a>	A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
<a href="#"><u>EAQ202</u></a>	Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
<a href="#"><u>S1912CD</u></a>	A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
<a href="#"><u>S2013</u></a>	<b>(Peoria, Bloomington, Galesburg, Pekin, Washington)</b> Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study <b>(I-CHECKIT)</b>
<a href="#"><u>URCC 16070</u></a>	Treatment of Refractory Nausea- for breast cancer patients.
<a href="#"><u>URCC-18007</u></a>	Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue in stage I-III Breast cancer pts.- <i>at least 2 months out from surgery/tx/radiation</i>
<a href="#"><u>URCC 21038</u></a>	<b>(Peoria Only)</b> Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
<a href="#"><u>WF-1901</u></a>	Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)

### **GYNECOLOGICAL**

**Navigator - Angie x3613**

<a href="#"><u>NRG - GY023</u></a>	A Randomized Phase II Trial of Triplet Therapy (a PD-L1 Inhibitor (Durvalumab) MEDI4736 in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or (Durvalumab) MEDI4736 and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab

## CANCER CONTROL

### MULTI-DISEASE SITES

<a href="#">A211901</a>	Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions
<a href="#">A222004</a>	A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
<a href="#">EAQ202</a>	Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
<a href="#">S1912CD</a>	A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
<a href="#">S2013</a>	<b>(Peoria, Bloomington, Galesburg, Pekin, Washington)</b> Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study (I-CHECKIT)
<a href="#">URCC 21038</a>	<b>(Peoria only)</b> Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
<a href="#">WF-1901</a>	Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)

### BREAST

<a href="#">A191901</a>	<b>(Peoria, Bloomington, Galesburg, Ottawa, Pekin, and Peru)</b> Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions <i>(only enrolling African American women )</i>
<a href="#">URCC 16070</a>	Treatment of Refractory Nausea- for breast cancer patients.
<a href="#">URCC-18007</a>	Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue in stage I-III Breast cancer pts.- <i>at least 2 months out from surgery/tx/radiation</i>

### LUNG

	Nothing currently available for Lung only - <i>See Multi-Disease Cancer Control trials ABOVE .</i>
--	--

### COLORECTAL

<a href="#">A221805</a>	Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
<a href="#">WF-1806</a>	(M&M Study) Myopenia and Mechanisms of Chemotherapy Toxicity in older Adults with Colorectal Cancer

### BRAIN

<a href="#">WF-1801</a>	A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy
-------------------------	--

### REGISTRY

Contact Disease Specific Navigator





ILLINOIS  
CANCERCARE, P.C.C.  
*Specializing in Cancer and Blood Disorders*

# MASTER TRIAL LIST

AUGUST 2022

[MENU](#)

**CARCINOID**

Navigator - Ashton x3611  
Carrie x3621

*No trials at this time*



# MASTER TRIAL LIST

AUGUST 2022



**CLL**

Navigator - Heather x3661

**1st Line**

**2nd Line, 3rd Line, etc.**

*no trials at this time*





ILLINOIS  
CANCERCARE, P.C.  
*Specializing in Cancer and Blood Disorders*

# MASTER TRIAL LIST

AUGUST 2022



MENU

*CML*

Navigator - Heather x3661

--	--

# MASTER TRIAL LIST

AUGUST 2022

MENU

**COLON / RECTAL**

Navigator - Carrie x3621

***Adjuvant***

<a href="#"><u>A021502</u></a>	Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
<a href="#"><u>C-14</u></a>	Second Colorectal Cancer Clinical Validation Study to Predict Recurrence Using A Circulating Tumor DNA Assay To Detect Minimal Residual Disease ( <b>CORRECT-MRD II</b> )
<a href="#"><u>GI005</u></a>	Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
<a href="#"><u>GI008</u></a>	<b>REOPENED</b> Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

***Metastatic***

<a href="#"><u>S2107</u></a>	Randomized Phase II Trial of Encorafenib and Cetuximab With or Without Nivolumab (NSC #748726) for Patients With Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
------------------------------	--

***CANCER CONTROL (Colorectal only)***

<a href="#"><u>A211901</u></a>	Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions
<a href="#"><u>A221805</u></a>	Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
<a href="#"><u>A222004</u></a>	A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
<a href="#"><u>EAQ202</u></a>	Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
<a href="#"><u>S1912CD</u></a>	A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
<a href="#"><u>S2013</u></a>	<b>(Peoria, Bloomington, Galesburg, Pekin, Washington)</b> Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study ( <b>I-CHECKIT</b> )
<a href="#"><u>URCC 21038</u></a>	<b>(Peoria Only)</b> Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
<a href="#"><u>WF-1901</u></a>	Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)

[WF-1806](#)

(M&M Study) Myopenia and Mechanisms of Chemotherapy Toxicity in older Adults with Colorectal Cancer



# MASTER TRIAL LIST

AUGUST 2022



## ESOPHAGEAL- GASTRIC

Navigator - Carrie x3621

[EA2174](#)

**(RT at Glen Oak, RT-91, UPHM, Galesburg)** A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma

## HEAD & NECK

Navigator - Ashton x3611

<p><a href="#"><u>EA3161</u></a></p>	<p><b>(RT at Glen Oak, UPH, Galesburg)</b> A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC</p>
<p><a href="#"><u>EA3191 - JIT</u></a></p>	<p><b>Temporarily Closed (RT at Route-91)</b> A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features</p>
<p><a href="#"><u>HN005</u></a></p>	<p><b>(RT at UPHM, Galesburg, Glen Oak)</b> A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer</p>
<p><a href="#"><u>HN009</u></a></p>	<p><b>(RT at UPHM)</b> Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin (100 mg/m<sup>2</sup>) Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin (40 mg/m<sup>2</sup>) for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)</p>



## LYMPHOMA

### HL

S1826

**(RT at Glen Oak, Rt-91, UPHM)** A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age  $\geq$  12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

### NHL

EA4181

A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients  $\leq$  70 Years Old With Untreated Mantle Cell Lymphoma

### SLL



ILLINOIS  
CANCERCARE, P.C.

*Specializing in Cancer and Blood Disorders*

# MASTER TRIAL LIST

AUGUST 2022

[MENU](#)

*MDS*

Navigator - Heather x3661

[NHLBI-MDS](#)

**(Peoria, Bloomington and Galesburg only)** -The National Myelodysplastic Syndromes (MDS) Study



# MASTER TRIAL LIST

AUGUST 2022

[MENU](#)

## MELANOMA

[Navigator - Carrie x3621](#)

[CA224098](#)

A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Metastatic or Unresectable Melanoma





ILLINOIS  
CANCERCARE, P.C.  
*Specializing in Cancer and Blood Disorders;*

# MASTER TRIAL LIST

AUGUST 2022

MENU

**MERKEL**

Navigator - Carrie x3621

**EA6174**

**(RT at Glen Oak, UPHM, Galesburg)** A Phase III Randomized Trial Comparing Adjuvant MK3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma



# MASTER TRIAL LIST

AUGUST 2022

MENU

## MOLECULAR STUDIES

\*Contact Disease Specific Navigator

<a href="#"><u>64091742PCR0002 / Prevalence</u></a>	Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer ( <b>Prevelence</b> )
<a href="#"><u>A151804</u></a>	Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
<a href="#"><u>NSABP C-14</u></a>	Second Colorectal Cancer Clinical Validation Study to Predict Recurrence Using A Circulating Tumor DNA Assay To Detect Minimal Residual Disease ( <b>CORRECT-MRD II</b> )
<a href="#"><u>S1823</u></a>	A Study of miRNA 371 in Patients With Germ Cell Tumor ( <i>closed to high risk pts or pts on chemo for testicular cancer</i> )
<a href="#"><u>TPX-0005-01 (TRIDENT-1)</u></a>	A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with <b>Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements</b> (TRIDENT-1)

# MASTER TRIAL LIST

AUGUST 2022



## ***MULTIPLE MYELOMA***

Navigator - Heather x3661

**S1803**

Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)

# MASTER TRIAL LIST

AUGUST 2022



## NEUROENDOCRINE

Navigator - Carrie x3621

[A021804](#)

A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma

**NSCLC**

Navigator - Ashton x3611

**ADJUVANT / NEOADJUVANT**

<a href="#"><u>A081801</u></a>	Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ALCHEMIST substudy- <i>Must be enrolled on ALCHEMIST and this substudy prior to start of tx</i> ).
<a href="#"><u>A151216</u></a>	Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial ( <b>ALCHEMIST</b> ).
<a href="#"><u>EA5181</u></a>	<b>(RT at UPHM and Galesburg)</b> Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC ( <b>credentialing pending at Glen Oak &amp; Rt-91</b> )
<a href="#"><u>GO41854</u></a>	<b>(Bloomington, Galesburg, Peoria, Peoria, Peru)</b> A Phase III, Open Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation ( <b>SKYSCRAPER-03</b> )
<a href="#"><u>S1914</u></a>	<b>(RT at Glen Oak, UPHM, Galesburg)</b> Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
<a href="#"><u>S1934 (JIT)</u></a>	Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer. <b>NASSIST</b> (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors)

**METASTATIC - 1st Line**

<a href="#"><u>EA5182</u></a>	Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
<a href="#"><u>MK 7684A-003</u></a>	<b>(Peoria only)</b> A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 with Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer
<a href="#"><u>TH-138</u></a>	<b>(Peoria, Bloomington, Galesburg, Peoria)</b> Phase II Randomized Trial of Carboplatin + Pemetrexed+ Bevacizumab, With or Without Atezolizumab in Stage IV Non-Squamous NSCLC Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked ( <b>non smokers</b> )

**METASTATIC - 2nd/3rd Line**

<a href="#"><u>LUNGMAP</u></a>	A Master Protocol To Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated NSCLC. <b>(SUB-STUDIES: S1800D</b> - A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy; <b>S1900E</b> - A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer ); <b>S1900F (coming soon!)</b> - A Randomized Phase II Study of Carboplatin and Pemetrexed w/ or w/o Selpercatinib in Participants With Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy)
<a href="#"><u>TH-138</u></a>	<b>(Peoria, Bloomington, Galesburg, Peoria)</b> Phase II Randomized Trial of Carboplatin + Pemetrexed+ Bevacizumab, With or Without Atezolizumab in Stage IV Non-Squamous NSCLC Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked ( <b>EGFR mutants</b> )

<b><u>A211901</u></b>	Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions
<b><u>A222004</u></b>	A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
<b><u>EAQ202</u></b>	Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
<b><u>S1912CD</u></b>	A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention ( <b>CREDIT</b> )
<b><u>S2013</u></b>	<b>(Peoria, Bloomington, Galesburg, Pekin, Washington)</b> Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study ( <b>I-CHECKIT</b> )
<b><u>URCC 21038</u></b>	<b>(Peoria Only)</b> Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
<b><u>WF-1901</u></b>	Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)



ILLINOIS  
CANCERCARE, P.C.  
*Specializing in Cancer and Blood Disorders*

# MASTER TRIAL LIST

AUGUST 2022



**MENU**

**PANCREATIC**

**Navigator - Carrie x3621**

**PROSTATE**

Navigator - Carrie x3621

**ADJUVANT**

<a href="#"><u>GU008</u></a>	<b>(RT at Glen Oak, UPHM)</b> Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE): <i>Intensifying Treatment for Node Positive Prostate Cancer by Varying the Hormonal Therapy</i>
<a href="#"><u>GU009</u></a>	<b>(RT at Glen Oak, Galesburg, UPHM)</b> Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation ( <b>PREDICT-RT*</b> )
<a href="#"><u>GU010</u></a>	<b>(RT at UPHM)</b> Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

**METASTATIC**

<a href="#"><u>64091742PCR0002 / Prevalence</u></a>	Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer
<a href="#"><u>C2321001</u></a>	<b>(Peoria only)</b> A Phase I Dose Escalation and Expanded Cohort Study of PF-06821497 in the Treatment of Adult Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL)
<a href="#"><u>A031902 / CASPAR</u></a>	A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer



<b><u>GU011</u></b>	<b>(RT at Glen Oak and UPHM)</b> A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadioTHErapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)
<b><u>S1802</u></b>	<b>(RT at Glen Oak, SJMC &amp; UPHM)</b> Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

# MASTER TRIAL LIST

AUGUST 2022



## RENAL CELL

Navigator - Carrie x3621

<p><a href="#"><u>A031704</u></a></p>	<p>PD-Inhibitor (nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer (PDIGREE)</p>
<p><a href="#"><u>MK 6482-011</u></a></p>	<p><b>(Peoria, Bloomington, Galesburg, Pekin)</b> An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy</p>

## RADIATION TRIALS

Navigator - Jessica x3615

CANCER CONTROL	
<a href="#"><u>WF-1801</u></a>	A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy
ANAL	
<a href="#"><u>EA2182</u></a>	<b>(UPHM and Glen Oak)</b> A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
BLADDER	
<a href="#"><u>A032002</u></a>	<b>(RT at Glen Oak)</b> Phase II Randomized Trial of Atezolizumab Versus Atezolizumab and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (ART)
<a href="#"><u>EA8185</u></a>	<b>(RT pending at Glen Oak &amp; Rt-91)</b> Phase 2 Study of Bladder-Sparing Chemoradiation With MEDI4736 (Durvalumab) in Clinical Stage 3, Node Positive Bladder Cancer (INSPIRE)
<a href="#"><u>S1806</u></a>	<b>(Glen Oak, SJMC, UPHM and Galesburg)</b> Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer
BRAIN	
<a href="#"><u>BN007</u></a>	<b>Temporarily Closed (UPHM, Glen Oak, Galesburg)</b> A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
<a href="#"><u>N0577</u></a>	<b>(Glen Oak, RT 91, and UPHM)</b> Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
BRAIN METS	
<a href="#"><u>A071801</u></a>	<b>(UPHM &amp; Glen Oak)</b> Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared With Fractionated SRS for Resected Metastatic Brain Disease

<b><u>CCTG CE.7</u></b>	<b>(UPHM &amp; Glen Oak)-</b> A Phase III Trial of Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases
<b>BREAST</b>	
<b><u>BR007</u></b>	<b>(Galesburg, Glen Oak, Rt 91, UPHM, SJMC)</b> Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
<b><u>MA.39</u></b>	<b>(Glen Oak and UPHM)</b> Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
<b>ESOPHAGEAL/GASTRIC</b>	
<b><u>EA2174</u></b>	<b>(Glen Oak, Rt 91, UPHM, Galesburg)</b> A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
<b>HEAD &amp; NECK</b>	
<b><u>EA3161</u></b>	<b>(Glen Oak, UPH, Galesburg)</b> A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
<b><u>HN005</u></b>	<b>(UPHM, Galesburg, Glen Oak)</b> A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
<b><u>HN009</u></b>	(RT at UPHM) Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin (100 mg/m <sup>2</sup> ) Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin (40 mg/m <sup>2</sup> ) for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
<b>HODGKIN'S LYMPHOMA</b>	
<b><u>S1826</u></b>	<b>(Glen Oak, Rt-91, UPHM)</b> A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
<b>MERKEL CELL</b>	
<b><u>EA6174</u></b>	<b>(Glen Oak, UPHM and Galesburg)</b> A Phase III Randomized Trial Comparing Adjuvant MK3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
<b>NSCLC</b>	

<a href="#"><u>EA5181</u></a>	<b>(UPHM and Galesburg)</b> Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC <b>(credentialing pending at Glen Oak)</b>
<a href="#"><u>S1914</u></a>	<b>(Glen Oak, UPHM, Galesburg)</b> Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
<b>PROSTATE</b>	
<a href="#"><u>GU008</u></a>	<b>(RT at Glen Oak, UPHM)</b> Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE): <i>Intensifying Treatment for Node Positive Prostate Cancer by Varying the Hormonal Therapy</i>
<a href="#"><u>GU009</u></a>	<b>(RT at Glen Oak, Galesburg, UPHM)</b> Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation <b>(PREDICT-RT*)</b>
<a href="#"><u>GU010</u></a>	<b>(RT at UPHM)</b> Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
<a href="#"><u>GU011</u></a>	<b>(RT at Glen Oak &amp; UPHM)</b> A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiothERapy With or Without ANDrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)
<a href="#"><u>S1802</u></a>	<b>(Glen Oak, SJMC &amp; UPHM)</b> Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
<a href="#"><u>WF-1802</u></a>	<b>(Glen Oak, Rt-91, UPHM, Galesburg)</b> Influence of Primary Treatment for Prostate Cancer on Work Experience (PCW)
<b>SCLC</b>	
<a href="#"><u>NRG CC009</u></a>	<b>(Glen Oak, UPHM)</b> - Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer

S1827

**(Glen Oak, UPHM, Galesburg, SJMC)** A Randomized Phase III Trial of MRI Surveillance With or Without Prophylactic Cranial Irradiation (PCI) in Small-Cell Lung Cancer

**SMALL CELL LUNG CANCER**

Navigator - Ashton x3611

<p><b><u>NRG CC009</u></b></p>	<p><b>(RT at Glen Oak, UPHM)</b> - Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer</p>
<p><b><u>GO43104</u></b></p>	<p><b>(Peoria, Bloomington, Galesburg, Ottawa, Pekin, Peru, Washington)</b> A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin In Combination With Atezolizumab Compared With Atezolizumab As Maintenance Therapy In Participants With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following First-Line Induction Therapy With Carboplatin, Etoposide and Atezolizumab</p>
<p><b><u>S1827</u></b></p>	<p><b>(RT at Glen Oak, UPHM, Galesburg, SJMC)</b> A Randomized Phase III Trial of MRI Surveillance With or Without Prophylactic Cranial Irradiation (PCI) in Small-Cell Lung Cancer</p>
<p><b><u>S1929</u></b></p>	<p>Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC) <i>Tissue screening allowed during induction chemotherapy</i></p>